Satellos Bioscience Inc.

MSCL

CA80401L3083

Biotechnology & Medical Research

Market Closed - Toronto S.E. Other stock markets 19:34:17 16/07/2024 BST			5-day change	1st Jan Change
0.485 ^CAD	+1.04%		-3.00%	+12.79%

07-11	Satellos Bioscience Submits Regulatory Filing for Phase 1 Clinical Trial With SAT-3247	MT
07-11	Satellos Bioscience Inc. Brief: Announcing Submission of Regulatory Filing to Commence a Phase 1 Clinical Trial with SAT-3247	MT

ICo Therapeutics Inc.(TSXV:ICO) dropped from S&P/TSX Venture Composite Index

January 18, 2016 at 05:00 am

iCo Therapeutics Inc.(TSXV:ICO) dropped from S&P/TSX Venture Composite Index

Latest news about Satellos Bioscience Inc.

Satellos Bioscience Submits Regulatory Filing for Phase 1 Clinical Trial With SAT-3247	07-11	MT
Satellos Bioscience Inc. Brief: Announcing Submission of Regulatory Filing to Commence a Phase 1 Clinical Trial with SAT-3247	07-11	MT
Satellos Announces Submission of Regulatory Filing to Commence A Phase 1 Clinical Trial with Sat-3247	07-11	CI
Satellos Bioscience Says Early Data Shows "Muscle Repair and Regeneration" from SAT-3247 Treatment in Canine Model	07-02	MT
Satellos Bioscience Inc. Brief: Presenting Preliminary Data Showing Muscle Repair and Regeneration from SAT-3247 Treatment in Canine Model of Duchenne Muscular Dystrophy	07-02	MT
Satellos Bioscience Inc. Presents Preliminary Data Showing Muscle Repair and Regeneration from SAT-3247 Treatment in Canine Model of Duchenne Muscular Dystrophy	07-02	CI
Satellos Bioscience Inc. Brief: Adds Trial will evaluate the safety and pharmacokinetic properties of SAT-3247 in healthy human volunteers	06-27	MT
Satellos Bioscience Inc. Brief: Co Says intends to submit a regulatory package in July to initiate a first-in-human Phase 1 clinical trial, in Q3 2024	06-27	MT
Satellos Bioscience Inc. Brief: Says CEO Frank Gleeson Participating at Parent Project Muscular Dystrophy (PPMD) 30th Annual Conference	06-27	MT
Satellos Bioscience Forms Advisory Board to Advance SAT-3247 in Duchenne Muscular Dystrophy Treatment	05-28	MT
Satellos Bioscience Inc. Brief: Announcing Formation of Clinical Advisory Board to Support Advancing SAT-3247 in Clinical Trial Development for Duchenne Muscular Dystrophy	05-28	MT
Satellos Bioscience Inc. Announces Formation of Clinical Advisory Board	05-28	CI
Satellos Bioscience Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
Satellos Bioscience Q1 Loss Widens Due To Higher Expenses; But Says "On track" to initiate Phase 1 First-in-human Clinical Trials Mid-2024	05-14	MT
Satellos Bioscience Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-27	CI
Satellos Bioscience Announces FY 2023 Results	03-27	MT
Satellos Presented "Positive" Preclinical Efficacy Data for SAT-3247 at the 2024 MDA Clinical & Scientific Conference	03-04	MT
Satellos Presents Positive Preclinical Efficacy Data for SAT-3247 at the 2024 MDA Clinical & Scientific Conference	03-04	CI
Satellos Bioscience Inc. Brief: Says Will commence trading on the Toronto Stock Exchange as of the opening of trading tomorrow	02-14	MT
Satellos Bioscience Inc. Announces Promising Preliminary Data in Facioscapulohumeral Muscular Dystrophy	02-13	CI
Satellos Bioscience Inc. Brief: Shares Jumped 13.4% on Monday; Co Recently Received Conditional Approval to Graduate to the Toronto Stock Exchange	01-23	MT
Satellos Bioscience Inc. Brief: Announced Earlier Tuesday Management Team Update; Alan K. Jacobs, Chief Medical Officer Has Left to Pursue Other Opportunities; Jordan Dubow Engaged As Chief Medical Advisor	01-23	MT
Satellos Bioscience Inc. Announces Executive Changes	01-23	CI
Satellos Receives Conditional Approval To Graduate To The Toronto Stock Exchange	01-16	MT
Satellos Bioscience Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-22	CI

Chart Satellos Bioscience Inc.

Duration

Period

More charts

Satellos Bioscience Inc. is a Canada-based a drug discovery and development company with a focus on muscle regeneration. The Company is focused on developing medicines to treat degenerative muscle conditions. Its MyoReGenX platform is specifically designed to recreate the specialized muscle stem cell niche in vitro. MyoReGenX platform enables to map pathways which modulate muscle repair and regeneration, identify, and confirm drug targets, and test drug candidates for their ability to restore muscle stem cell repair mechanisms that have been impaired by genetic mutations, disease or injury. Its lead program is an oral, small molecule drug candidate in development as a disease-modifying treatment for Duchenne muscular dystrophy. Its iCo portfolio includes Oral Amp B Delivery System, a patented oral transport technology and Bertilimumab a human monoclonal eotaxin antibody with potential to treat a range of allergic and inflammatory conditions mediated by eotaxin-1.

Sector

Biotechnology & Medical Research

Calendar

25/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.485 CAD

Average target price

1.2 CAD

Spread / Average Target

+147.42%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SATELLOS BIOSCIENCE INC.	+12.79%	39.64M
VERTEX PHARMACEUTICALS INCORPORATED	+20.17%	127B
REGENERON PHARMACEUTICALS, INC.	+24.67%	117B
ARGENX SE	+25.44%	27.67B
BIONTECH SE	-17.74%	20.33B
GENMAB A/S	-15.17%	16.79B
BEIGENE, LTD.	-15.21%	15.63B
NEUROCRINE BIOSCIENCES, INC.	+11.91%	14.84B
WUXI APPTEC CO., LTD.	-47.10%	14.65B
SAREPTA THERAPEUTICS, INC.	+54.50%	14.43B

Bio Therapeutic Drugs

Satellos Bioscience Inc.

Equities

MSCL

CA80401L3083

Biotechnology & Medical Research

ICo Therapeutics Inc.(TSXV:ICO) dropped from S&P/TSX Venture Composite Index

Latest news about Satellos Bioscience Inc.

Chart Satellos Bioscience Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs